GlaxoSmithKline

Medicines Patent Pool collaborates with ViiV Healthcare

Friday, March 1, 2013 12:39 PM

The Medicines Patent Pool (MPP) has launched a collaboration with ViiV Healthcare—a joint venture of GlaxoSmithKline, Pfizer and Shionogi—to facilitate greater availability of critically needed medicines for children living with HIV.

More... »

Ernest Mario named chairman of Chimerix

Wednesday, February 20, 2013 12:25 PM

Chimerix, a Durham, N.C.-based biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, has appointed Ernest Mario, Ph.D., as chairman of its board of directors.

More... »

GSK supports AllTrials campaign for clinical data transparency

Wednesday, February 6, 2013 10:14 AM

GlaxoSmithKline (GSK) has further demonstrated its commitment to clinical trial transparency by announcing its support for the AllTrials campaign. The campaign is calling for registration of clinical trials and the disclosure of clinical trial results and clinical study reports (CSRs) to help drive further scientific understanding.

More... »

ClinPharm Consulting changes name to Kinetigen

Monday, February 4, 2013 11:26 AM

ClinPharm Consulting, a specialty pharmaceutical consulting firm with global reach, has changed its name to Kinetigen. All management, scientific and operational components of Kinetigen remain the same as under ClinPharm, including the consulting firm’s focus on clinical pharmacology and pharmacokinetics.

More... »

CDISC names additions to board of directors

Friday, January 25, 2013 12:27 PM

CDISC, a global, open, non-profit organization that has established standards to support the acquisition, exchange, submission and archive of clinical research data and metadata, has named five highly qualified individuals that will add invaluable expertise to the CDISC board of directors (BoD) for a three-year term beginning this month (2013–2016): Dr. Carolyn Compton, Michael Glickman, Dr. Douglas Peddicord, Stephen Pyke and John Speakman.

More... »

GSK submits albiglutide BLA to FDA for T2D

Monday, January 14, 2013 02:20 PM

GlaxoSmithKline (GSK), a global research-based pharmaceutical and healthcare company, announced a regulatory submission to the FDA for albiglutide, an investigational once-weekly treatment for adult patients with type 2 diabetes. 

More... »

Priaxon, GSK collaborate on PPIs

Wednesday, January 9, 2013 11:39 AM

Priaxon, an emerging pharmaceutical company based in Germany, has formed a collaboration with GlaxoSmithKline (GSK) to research and develop small molecule modulators of protein-protein-interactions.

More... »

Ambrx appoints Macartney as CEO

Tuesday, January 8, 2013 08:00 AM

Ambrx, a clinical-stage biopharmaceutical company using an expanded genetic code to create best-in-class biotherapeutics, has appointed Lawson Macartney, Ph.D., DVM, as president and CEO of the company and a member of the board of directors.

More... »

New company NeRRe Therapeutics created to develop neurokinin antagonists from GSK

Wednesday, December 19, 2012 10:42 AM

NeRRe Therapeutics, a new drug discovery company, has been launched to develop a portfolio of clinical and pre-clinical neurokinin receptor antagonists divested from GlaxoSmithKline (GSK).

More... »

FDA approves GSK's four-strain seasonal influenza vaccine

Monday, December 17, 2012 04:28 PM

The FDA has approved GlaxoSmithKline’s Fluarix Quadrivalent (influenza virus vaccine) for the immunization of adults and children (three years and older) to help prevent disease caused by seasonal influenza virus subtypes A and B contained in the vaccine.

More... »